New oral cancer drug enters human testing for advanced solid tumors
Disease control
Ongoing
This early-stage study is testing a new oral medication called ATRN-119 in patients with advanced solid tumors that have specific genetic mutations. The main goals are to check the drug's safety, how it moves through the body, and see if it shows any early signs of effectiveness …
Phase: PHASE1, PHASE2 • Sponsor: Aprea Therapeutics • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC